Insight Molecular Diagnostics (IMDX) risk factors, FY2024 10-K

Risks Related to Our Capital Resources

1. 01We have incurred operating losses since inception, and we do not know if we will attain profitability
2. 02We have historically been dependent upon outside financing capital to fund our operations and until such time as our revenues are sufficient to finance our operating expenses, we may need to issue additional equity or debt securities to raise the capital needed to pay our operating expenses
3. 03We may incur significant cash payment and common stock issuance obligations under our agreements arising from our investments in Insight and Chronix

Risks Related to Our Business Operations

1. 04Our revenues in the near term will depend on our ability to commercialize a small number of diagnostic tests
2. 05The research and development work we are doing is costly, time consuming, and uncertain as to its results
3. 06Sales of our diagnostic tests could be adversely impacted by the reluctance of physicians to adopt the use of our tests and by the availability of competing diagnostic tests
4. 07There is a risk of product liability claims in our business. If we are unable to obtain or maintain sufficient insurance, a product liability claim against us could adversely affect our business
5. 08We have limited capital, marketing, sales, and regulatory compliance resources for the commercialization of our diagnostic tests
6. 09We may face technology transfer challenges and expenses in adding new tests to our portfolio and in expanding our reach into new geographical areas on new instrument platforms
7. 10If our laboratory facilities become damaged or inoperable, or we are required to vacate any facility, our ability to provide services and pursue our research and development and commercialization efforts may be jeopardized
8. 11There is a limited number of manufacturers of molecular diagnostic testing equipment and related chemical reagents necessary for the provision of our diagnostic tests
9. 12If we fail to enter into and maintain successful strategic alliances for diagnostic tests that we elect to co-develop, co-market, or out-license, we may have to reduce or delay our diagnostic test development or increase our expenditures
10. 13We are, and in the future, may become, dependent on collaborations to develop and commercialize many of our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business
11. 14Our business could be adversely affected if we lose the services of the key personnel upon whom we depend
12. 15Our business and operations could suffer in the event of system failures
13. 16Security breaches and other disruptions could compromise our information and expose us to liability, and could cause our business and reputation to suffer
14. 17Failure of our internal control over financial reporting could harm our business and financial results
15. 18We are subject to laws and regulations governing corruption, which may require us to develop, maintain, and implement costly compliance programs
16. 19We may in the future be subject to litigation, which could harm our stock price, business, results of operations and financial condition
17. 20We may undertake strategic acquisitions in the future, and difficulties integrating such acquisitions could damage our ability to achieve or sustain profitability
18. 21We are subject to state laws in California that require gender and diversity quotas for boards of directors of public companies headquartered in California
19. 22Our business could be adversely impacted by inflation

Risks Related to Our Industry

1. 23We will also need to obtain FDA and other regulatory approvals for any IVDs that we may develop, or for any currently marketed products the FDA determines are IVDs instead of LDTs, in order to market those IVD tests
2. 24Clinical trial failures can occur at any stage of the testing and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future diagnostic tests
3. 25Inability or unwillingness of medical investigators to follow our clinical protocols
4. 26The commercial success of our diagnostic tests depends on the availability and sufficiency of third-party payer coverage and reimbursement, which may be limited or unavailable
5. 27Changes in healthcare laws and policies may have a material adverse effect on our financial condition, results of operations and cash flows
6. 28Because of certain Medicare billing policies, we may not receive complete reimbursement for tests provided to Medicare patients
7. 29Long payment cycles of Medicare, Medicaid and other third-party payers, or other payment delays, could hurt our cash flows and increase our need for working capital
8. 30Private health insurance company policies may deny coverage or limit the amount they will reimburse us for the performance of our diagnostic tests
9. 31We will be required to comply with federal and state laws governing the privacy of health information, and any failure to comply with these laws could result in material criminal and civil penalties
10. 32Tariff policies and potential countermeasures could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations

Risks Related to Intellectual Property

1. 33We rely on patents and trade secrets, and our financial success will depend, in part, on our ability to obtain commercially valuable patent claims, protect our intellectual property rights and operate without infringing upon the proprietary rights of others
2. 34We may not be able to obtain patent protection for our diagnostic tests if our pending U.S. patent applications are found to be directed to unpatentable subject matter
3. 35Changes to the patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our diagnostic tests
4. 36Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our diagnostic tests
5. 37If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, and our business would be harmed
6. 38We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
7. 39We may not be able to enforce our intellectual property rights throughout the world
8. 40If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our diagnostic tests
9. 41Failure to adequately protect, or disputes relating to, trademarks or patents, could harm our business
10. 42Patent terms may be inadequate to protect our competitive position on our diagnostic tests for an adequate amount of time
11. 43Obtaining and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case of non-compliance with these requirements

Risks Related to Our Common Stock

1. 44Because we do not pay dividends, our stock may not be a suitable investment for anyone who needs to earn dividend income
2. 45Securities analysts may not initiate coverage or continue to cover our common stock, and this may have a negative impact on the market price of our shares
3. 46You may experience dilution of your ownership interests if we issue additional shares of common stock or preferred stock
4. 47Our former parent company may sell our shares to raise capital to finance its operations
5. 48We are a “smaller reporting company” under the SEC’s disclosure rules and have elected to comply with the reduced disclosure requirements applicable to smaller reporting companies